Progressive multi-focal leucoencephalopathy – driven from rarity to clinical mainstream by iatrogenic immunodeficiency

Clinical and Experimental Immunology

Volumn 188, Issue 3, 2017, Pages 342-352

  Misbah, S A ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

cell trafficking; EAE MS; immunodeficiency diseases; neuroimmunology; viral

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL PRODUCT; BRENTUXIMAB VEDOTIN; ECULIZUMAB; EFALIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ESTER; IBRUTINIB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; HUMAN; IATROGENIC DISEASE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; ADVERSE EFFECTS; BRAIN; DISEASE MANAGEMENT; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; POLYOMAVIRUS INFECTIONS; VIROLOGY;

ANTIBODIES, MONOCLONAL; BRAIN; DISEASE MANAGEMENT; HUMANS; IATROGENIC DISEASE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; POLYOMAVIRUS INFECTIONS;

EID: 85017376722     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12948     Document Type: Review

References (102)

1. Astrom KE, Mansell EL, Richardson EP Jr. Progressive multifocal leukoencephalopathy: a hitherto unrecognised complication of chronic lymphocytic leukaemia and Hogkin's disease. Brain 1958; 81:93–111.
2. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1:1257–60.
3. Misbah SA, Spickett GP, Zeman A et al. Progressive multifocal leukoencephalopathy, sclerosing cholangitis, bronchiectasis and disseminated warts in a patient with primary combined immune deficiency. J Clin Path 1992; 45:624–7.
4. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001; 75:3483–7.
5. Wollebo HS, White MK, Gordon J, Berger JR, Khalili K. Persistence and pathogenesis of the neurotropic polyoma virus JC. Ann Neurol 2015; 77:560–70.
6. Dorries K, Vogel E, Gunther S, Czub S. Infection of human polyoma viruses JC and BK in peripheral blood leucocytes from immunocompetent individuals. Virology 1994; 198:59–70.
7. Assetta B, Maginnis MS, Ahufinger IG et al. 5-HT2 receptors facilitate JC polyoma virus entry. J Virol 2013; 87:13490–8.
8. Frohman EM, Monaco MC, Remington G et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014; 71:596–602.
9. Chalkias S, Dang X, Bord E et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 2014; 75:925–34.
10. Warnke C, Adams O, Kieseier B. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis. JAMA Neurol 2014; 71:1192.
11. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 2008; 64:379–87.
12. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Ann Rev Med 2010; 61:35–47.
13. Ciappi S, Azzi A, De Santis R et al. Archetypal and rearranged sequences of human polyoma virus JC transcription control region in peripheral blood leucocytes and in cerebrospinal fluid. J Gen Virol 1999; 80:1017–23.
14. Van Loy T, Thys K, Ryschkewitsch C et al. JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the haematogenous route. J Virol 2015; 89:1340–7.
15. Sindic CJ, Trebst C, Van Antwerpen MP et al. Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. J Neuroimmunol 1997; 76:100–4.
16. Sindic CJ, Monteyne P, Laterre EC. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J Neuroimmunol 1994; 54:75–80.
17. Luxton RW, Zeman A, Holzel H et al. Affinity of antigen-specific IgG distinguishes multiple sclerosis from encephalitis. J Neurol Sci 1995; 132:11–9.
18. Koralnik IJ, Du Pasquier RA, Kuroda MJ et al. Association of prolonged survival in HLA-A2+ progressive multifocal leucoencephalopathy patients with a cytotoxic T lymphocyte response specific for a commonly recognised JC virus epitope. J Immunol 2002; 168:499–504.
19. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leucoencephalopathy. Brain 2004; 127:1970–8.
20. Wuthrich C, Kesari S, Kim WK et al. Characterization of lymphocytic infiltrates in progressive multifocal leucoencephalopathy: co-localization of CD8 T cells with JCV-infected glial cells. J Neurovirol 2006; 12:116–28.
21. Gheuens S, Bard E, Kesari S et al. Role of CD4+ and CD8+ T cell responses against JC virus in the outcome of patients with progressive multifocal leucoencephalopathy (PML) and PML with immune reconstitution syndrome. J Virol 2011; 85:7256–63.
22. Aly L, Yousef S, Schippling S et al. Central role of JC virus-specific CD4+ lymphocytes in PML-immune reconstitution syndrome. Brain 2011; 134:2687–702.
23. Yousef S, Planas R, Chakroun K et al. TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus specific CD4+ T cells during viral infection. J Immunol 2012; 189:3618–30.
24. Qin Q, Shwetank, Frost EL, Maru S, Lukacher AE. Type I interferons regulate the magnitude and functionality of mouse polyomavirus-specific CD8 T cells in a virus strain-dependent manner. J Virol 2016; 90:5187–99.
25. O'Hara BA, Atwood WJ. Interferon β1-a and selective anti-5HT2a receptor antagonists inhibit infection of human glial cells by JC virus. Virus Research 2008; 132:97–103.
26. Assetta B, De Cecco M, O'Hara B, Atwood WJ. JC polyomavirus infection of primary human renal epithelial cells is controlled by a type I IFN-induced response. mBio 2016; 7:e00903-16
27. Delbue S, Guerini FR, Mancuso R et al. JC virus viraemia in interferon-β-treated and untreated Italian multiple sclerosis patients and healthy controls. J Neurovirol 2007; 13:73–7.
28. Zerbe CS, Marciano BE, Katial RK et al. Progressive multifocal leukoencephalopathy in primary immune deficiencies: STAT-1 gain of function and review of the literature. Clin Infect Dis 2016; 62:986–94.
29. Tan CS, Bord E, Broge TA Jr et al. Increased programmed cell death-1 expression on T lymphocytes of patients with progressive multifocal leucoencephalopathy. J Acquir Immune Def Syn 2012; 60:244–8.
30. Berger JR, Aksamit AJ, Clifford DB et al. PML diagnostic criteria. Consensus statement from the American Academy for Neurology Neuroinfectious Disease Section. Neurology 2013; 80:1430–8.
31. Mentzer D, Prestel J, Adams O et al. Case definition for progressive multifocal leucoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry 2012; 83:927–33.
32. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. PML in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007; 56:2116–28.
33. Molloy ES, Calabrese LH. PML in patients with rheumatic diseases: are patients with SLE at particular risk? Autoimmunity Rev 2008; 8:144–6.
34. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992; 356:63–6.
35. Langer- Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. PML in a patient treated with Natalizumab. N Engl J Med 2005; 353:375–81.
36. Kleinschmidt-De Masters BK, Tyler KL. PML complicating treatment with Natalizumab and interferon β-1a for multiple sclerosis. N Engl J Med 2005; 353:369–74.
37. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with Natalizumab for PML. N Engl J Med 2006; 354:924–33.
38. Berger JR, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol 2016; 22:533–5.
39. Chalkley JJ, Berger JR. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep 2013; 13:408.
40. Defer G, Mariotte D, Derache N et al. CD49d expression as a promising biomarker to monitor natalizumab efficacy. J Neurol Sci 2012; 314:138–42.
41. Schwab N, Schneider-Hohendorf T, Posevitz V et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81:865–71.
42. Pignolet B, Schwab N, Schneider-Hohendorf T et al. CD62L test at 2 years of Natalizumab predicts progressive multifocal leukoencephalopathy. Neurology 2016; 87:1–3.
43. Lieberman LA, Zeng W, Singh C et al. CD62L is not a reliable marker for predicting PML risk in natalizumab-treated relapsing–remitting multiple sclerosis patients. Neurology 2016; 86:375–81.
44. Colombel JF, Sands BE, Rutgeerts P et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2016; pii: gutjnl-2015-311079. doi: 10.1136/gutjnl-2015-311079. [Epub ahead of print]
45. Crason KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol 2009; 10:816–24.
46. Schwab N, Ulzheimer JC, Fox RJ et al. Fatal PML associated with efalizumab therapy – insights into integrin αLβ2 in JC virus control. Neurology 2012; 78:458–67.
47. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab and immunosuppression – a cautionary tale for dermatologists. Arch Dermatol 2009; 145:937–42.
48. Bartsch T, Rempe T, Wrede A et al. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 2015; 78:501–14.
49. Nieuwkamp DJ, Murk JL, van Oosten BW et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015; 372:1474–6.
50. US Food and Drug Administration. FDA Alert Rituximab-PML [12/ 2006]. Available at: www.fda.gov/Drugs/DrugSafety/…/ucm126519.htm (accessed 1 November 2016).
51. US Food and Drug Administration. FDA Alert Rituximab-PML posted 23.10. 2009 https://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM187792.pdf (accessed 1 November 2016).
52. Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75:1326–32.
53. Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68:1156–64.
54. Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013; 65:2783–90.
55. Wilk E, Witte T, Marquardt N et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009; 60:3563–71.
56. Raisch DW, Rafi JA, Cheng C, Bennett CL. Detection of cases of PML associated with new biologicals and targeted cancer therapies from the FDA's adverse drug reporting system. Expert Opin Drug Saf 2016; 15:1003–11.
57. Carson KR, Newsome SD, Kim EJ et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy – a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014; 120:2464–71.
58. Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated PML. N Engl J Med 2012; 366:1870–80.
59. Molloy ES, Calabrese LH. Therapy: targeted but not trouble-free. Nat Rev Rheumatol 2009; 5:418–9.
60. Isidoro L, Pires P, Rito L, Cordeiro G. Progressive multifocal leukoencephalopathy in a patient with CLL treated with alemtuzumab. BMJ Case Rep 2014; 2014: bcr2013201781.
61. D'Souza A, Wilson J, Mukherjee S, Jaiyesimi I. Progressive multifocal leukoencephalopathy in CLL: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010; 4:e2012043.
62. Waggoner J, Martinu T, Palmer SM. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 2009; 28:395–8.
63. Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. Br Med J 2016; 354:i3518.
64. Tuohy O, Costelloe L, Hill-Cawthorne G et al. Alemtuzumab treatment of multiple sclerosis: long term safety and efficacy. J Neurol Neurosurg Psychiatry 2015; 86:208–15.
65. Jones JL, Thompson SA, Loh P et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T cell proliferation. Proc Natl Acad Sci USA 2013; 110:20200–5.
66. Gomez-Cibeira E, Ivanovic-Barbeito Y, Gutierrez- Martinez E et al. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology 2016; 86:399–400.
67. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leucoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010; 62:3191–5.
68. Sammut L, Wallis D, Holroyd C. Progressive multifocal leucoencephalopathy associated with infliximab. J R Coll Physicians Edinb 2016; 46:163–5.
69. Ray M, Curtis JR, Baddley JW. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis 2014; 73:1429–30.
70. Graff-Radford J, Robinson MJ, Warsame RM, Matteson EL, Eggers SD, Keegan BM. Progressive multifocal leukoencephalopathy in a patient treated with etanercept. Neurologist 2012; 18:85–7.
71. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethyl fumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121:1383–8.
72. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26:2067–74.
73. Vandermeeren M, Janssens S, Wouters H et al. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappaB1, but not ReIA in normal human dermal fibroblast cells. J Invest Dermatol 2001; 116:124–30.
74. Rubant SA, Ludwig RJ, Diehl S et al. Dimethy fumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol 2008; 128:326–31.
75. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368:1657–8.
76. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethylfumarate from a compounding pharmacy. N Engl J Med 2013; 368:1658–9.
77. Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015; 372:1476–8.
78. Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM. Non fatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Nuerol Neuroimmunol Neuroinflamm 2016; 3:e274.
79. Fox RJ, Chan A, Gold R et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS. Neurology Clin Pract 2016; 6:1–10.
80. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS. Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neurinflamm 2015; 2:e76.
81. Draayer YM, Sarazin J, Fox D, Schiopu E. The sphingosine-1- phosphate receptor: a novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin Immunol 2017; 175:10–5.
82. European Medicines Agency. New recommendations to minimise risk of the rare brain infection PML and a type of skin cancer with Gilenya. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&mid=WC0b01ac058004d5c1 (accessed 13 December 2016).
83. Stuve O, Cravens PD, Frohman EM et al. Immunologic, clinical and radiologic status 14 months after cessation of Natalizumab therapy. Neurology 2009; 72:396–401.
84. Lutz M, Schulze AB, Rebber E et al. Progressive multifocal leukoencephalopathy after Ibrutinib treatment for chronic lymphocytic leukaemia. Cancer Res Treat 2016; doi 10.4143.
85. Bennett CL, Berger JR, Sartor O et al. Progressive multifocal leukoencephalopathy among ibrutinib-treated patients with chronic lymphocytic leukaemia. Br J Haem 2016; doi 10.1111/bjh 14322
86. Dobovsky JA, Beckwith KA, Natarajan G et al. Ibrutinib is an irreversible inhibitor of ITK driving a TH1-selective pressure in T lymphocytes. Blood 2013; 122:2539–49.
87. Ahn IE, Jerussi T, Farooqui M, Wiestner A, Gea-Banacloche J. Atypical pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single agent ibrutinib. Blood 2016; 128:1940–3.
88. Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013; 369:197–8.
89. Melis M, Biagi C, Smabrekke L et al. Drug-induced progressive multifocal leukoencephalopathy: a comprehensive analysis of the WHO adverse drug database. CNS Drugs 2015; 29:879–91.
90. De-Simone FI, Sariyar R, Otalora YL et al. IFN-gamma inhibits JC virus replication in glial cells by suppressing T-antigen expression. PLOS ONE 2015; 10:e0129694.
91. Day-Williams AG, Sun C, Jelcic I et al. Whole genome sequencing reveals a chromosome 9p deletion causing DOCK8 deficiency in an adult with diagnosed with hyper-IgE syndrome who developed progressive multifocal leukoencephalopathy. J Clin Immunol 2015; 35:92–6.
92. Angelini L, Pietrogrande MC, Delle Paine MR et al. Progressive multifocal leukoencephalopathy in a child with hyperimmunoglobulin E recurrent infection syndrome and review of the literature. Neuropediatrics 2001; 32:250–5.
93. Schroder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010; 67:1391–4.
94. Miskin DP, Chalkias SG, Dang X, Bord E, Batson S, Koralnik IJ. Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia. Neurol Neuroimmunol Neuroinflamm 2016; 3:e213.]
95. Middel A, Arends JE, van Lelyveld SFL et al. Clinical and immunologic effects of maraviroc in progressive multifocal leukoencephalopathy. Neurology 2015; 85:104–6.
96. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66:255–8.
97. Hall CD, Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998; 338:1345–51.
98. De Luca A, Ammassari A, Pezzotti P et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multi-cohort analysis. AIDS 2008; 22:1759–67.
99. Brickelmaier M, Lugovsky A, Kartikeyan R et al. Identification and characterisation of mefloquine efficacy against JC virus in-vitro. Antimicrobial Agents Chemother 2009; 53:1840–9.
100. Nukuzuma S, Nakamichi K, Kameoka M et al. Suppressive effects of topoisomerase inhibitors on JC polyomavirus propagation in human neuroblastoma cells. Microbiol Immunol 2016; 60:253–60.
101. Marzocchetti A, Tompkins T, Clifford DB et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73:1551–8.
102. Garcia-Suarez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80:271–81.